XML 17 R7.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (13,348,123) $ (22,492,573)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation 473,311 28,670
Stock-based compensation from asset purchase 10,000 6,712,663
Depreciation expense 135,498 300,129
Amortization of intangible assets 1,667 1,666
Amortization of debt discount - note payable 1,412,530 1,192,418
Amortization of debt discount - note receivable, related party (99,897)
Loss on note exchange agreement 208,670
Change in fair value of derivative liability (14,125)
Change in fair value of Evofem warrants 63,211
Changes in operating assets and liabilities:    
Accounts receivable 3,692 1,732
Prepaid expenses (59,237) (225,898)
Deposits (128,274) (572)
Inventory 3,628 180,001
Accounts payable and accrued expenses (2,552,013) 5,122,287
Settlement liability 720,000
Net cash used in operating activities (14,098,132) (8,250,807)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Investment in notes receivable and warrants, related party (2,425,000)
Investment in Evofem preferred stock (1,000,000)
Net cash provided by investing activities (2,425,000) (1,000,000)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from notes payable, related party 493,000 467,000
Proceeds from notes and convertible notes payable, net of offering costs 1,504,019 2,393,811
Repayments of note payable, related party (608,000) (375,000)
Repayments of note payable (3,926,760) (2,156,052)
New principal from extension of notes, net of debt discount 451,974
Common stock and warrants issued for cash, net of issuance costs 24,777,835 3,018,567
Cash from subscription receivable 1,108,751 5,444,628
Redemptions of A-1 preferred stock (308,000)
Redemptions of C-1 preferred stock (7,027,065)
Net cash provided by financing activities 16,013,780 9,244,928
NET DECREASE IN CASH (509,352) (5,879)
CASH AT BEGINNING OF PERIOD 833,031 97,102
CASH AT END OF PERIOD 323,679 91,223
Supplemental cash flow information:    
Cash paid for income taxes
Cash paid for interest 1,264,504 622,762
NONCASH INVESTING AND FINANCING ACTIVITIES:    
Issuance of shares for the conversion of notes payable 500,000
Debt discount from shares issued as inducement for note payable 662,718
Warrant modification 4,137
Issuance of shares in asset purchase 266,448
Shares issued for settlement 160,000
Return of notes payable from Evofem merger agreement 11,174,246
Accrued interest rolled into notes payable 583,223
ELOC payable 630,105
Series C-1 redemption payable 2,602,045
ELOC commitment fee stock payable 2,250,000
Loan in escrow 2,000,000
Reclassification of series A-1 preferred shares to liabilities $ 517,444